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1. Introduction
Stress urinary incontinence (SUI) is the prevalent form of urinary tract infection [1], affecting
nearly 34 million women in the US [2,3]. In men undergoing prostatectomy, postoperative
removal of the catheter leads to urine leakage due to SUI in 50% of cases [4]. The costs of
medicine and health care related to SUI are estimated to be $26 billion US dollars annually [5].
Damage to the sphincter muscle around the middle segment of urethra and its connective
tissue and nerves is a major cause of SUI [6]. The urethra consists of proximal, middle, and
distal segments. The midurethra is a critical component in the urethral sphincter complex,
which mainly consists of the inner smooth muscle and outer striated muscles. The striated
muscle contributes the most to the complex. Urethral striated muscle is significantly reduced
with increasing age. Thus, in patients with SUI, when the lost striated muscle can be restored,
amelioration of SUI can be expected. Otherwise, the smooth muscle plays a lesser role, but it
is still a desirable treatment target to recover sphincter function [7]. Strategies to replace
skeletal muscle cells with stem cell therapy could be used in treatment of SUI.
2. Cell therapy for USI
Pharmaceutical treatment of SUI has not been successful [8]; in addition, periurethral injection
of bulking agents has poor long-term efficacy and is associated with complications such as
voiding dysfunction, abscess formation, and pulmonary embolism [9]. Several surgical
procedures such as urethral sling surgery or installation of an artificial sphincter have been
used to treat patients with SUI over last three decades [10]. Although these procedures can
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reinforce weak muscle tissue at the pelvic floor or around the urethra, deficient urethral
sphincter function remains. Furthermore, surgery for SUI sometimes causes complications
such as infection and postoperative voiding difficulty [11]. Autologous adult stem cell injection
therapy for SUI has recently provided a promising alternative for sphincter tissue regeneration
for repair of SUI. Stem cells obtained from skeletal muscle [12], bone marrow [13-15], umbilical
cord [16], adipose tissue [17], and more recently, induced pluripotent cells [18] are regarded
as possible candidates for use in this therapy. However, harvesting these types of cells is
invasive and may cause complications. Furthermore, the amount of tissue that can be safely
harvested in some patients, such as skeletal muscle-derived progenitor cells or bone marrow
stem cells (BMSCs) in older individuals, limits clinical applications [19]. Thus, an autologous
stem cell source that can be obtained using non invasive techniques would be desirable.
Mesechymal stem cells (MSCs) are often used as a cell source for cell therapy in two ways.
First, stem cells are implanted directly into the tissues where repair is needed. By secreting
paracrine factors, MSCs promote angiogenesis, decrease fibrosis, and recruit stem cells from
native tissues to complete the repair, replacement, and regeneration processes at the injured
sites. In addition, the surrounding normal cell- and tissue-based signals from the host envi‐
ronment guide the undifferentiated stem cells to give rise to the specific target cells required
for tissue regeneration [20]. Second, stem cells are induced to differentiate into the target cells
or tissue–like cells in vitro. The induced cells are then implanted into defective sites where
normal cells and tissues are not available.
In clinical settings, most patients with SUI acquire chronic injuries related to urethral dys‐
function spanning years or even decades. In cases with extensive injuries and fibroblast
formation, it would be better to induce the stem cells to differentiate into a myogenic lineage
before injection, since the unhealthy or diseased environment (e.g. muscular dystrophy) may
not be able to provide efficient differentiation cues required for efficient stem cells differen‐
tiation. Therefore, our strategy is to guide USCs to give rise to myogenic differentiation and
then lead to repairing the deficiency, and also determine whether USCs can secrete paracrine
factors to recruit the resident cells from the host to participate in tissue repair.
3. Stem cell properties of urine-derived cells
Tissue-specific stem cells are rare in each tissue or organ. These cells play an important role in
replacing aged, injured, and diseased cells and promoting tissue regeneration. However, it is
a challenge to isolate these cells for therapeutic purposes. Recently, we successfully established
a primary culture system to isolate and repopulate stem cells from regular voided human urine
[21]. These cells possess stem cell properties, such as robust proliferation potential and
multipotential differentiation capabilities, and are termed urine-derived stem cells (USCs) [22]
(Fig.1). USCs expressed a whole set of MSC/pericyte markers and some key cell surface
markers, such as CD 105, CD 90, CD 73, and CD 146, but not hematopoietic stem cell makers
such as CD 31 and CD34 [21, 23](Fig.2). These cells maintain high telomerase activity and a
normal karyotype in culture medium, even after several passages. The cells can differentiate
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into mesodermal cell lineages, such as osteocytes, chondrocytes, adipocytes, and myocytes,
including smooth muscle cell differentiation and endodermal lineages (e.g. endothelial and
urothelial cells) [23,24]. Additionally, USCs can be isolated and cultured from almost every
urine sample. Our recent data demonstrate that 100 ml of urine contains about 3-10 USC clones
[23]. On average, 12 USC clones can be isolated from one urine sample (about 200 ml). To
induce stem cells to differentiate into skeletal muscle cells more efficiently, cells at the early
passage are recommended. Usually, it takes 4 weeks for one cell clone to generate 3.2X107cells
at an early passage (p4) [24]. Therefore, at least 4x108 USCs (12x3.2 x 107cells) can be generated
from one urine sample, which are enough cells for use in the treatment of any grade of SUI.
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Figure 1. Morphology of USC: Phase contrast microscopic appearances of urine derived stem cell clones showing
“rice-grain” like morphology.
Figure 2. Stem cell surface marker of USC cell clones.
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4. Myogenic differentiation of USCs
Our previous studies demonstrated that USCs can be efficiently induced to differentiate into
smooth muscle cells [23, 24]. After myogenic differentiation with TGF-1 (2.5 ng/ml) and PDGF-
BB (5.0 ng/ml), induced USCs displayed spindle-shape morphology, and expressed smooth
muscle-specific gene and protein markers (such as smoothelin, myosin, and desmin). In
addition, these cells exhibited a contractile pattern similar to bladder smooth muscle cells. In
our recent study, we demonstrated that USCs can give rise to skeletal muscle-like cells with
myotube formation in standard myogenic differentiation media (i.e. SkGM2/Differentiation
Medium. USCs are culture in Sk-MC growth Medium (SkGM-2, Lonza) for 2 weeks followed
by Differentiation medium (DMEM:F-12 [1:1], 2% Horse serum and 1% Penecillin/streptomy‐
cin). Differentiated USCs expressed specific skeletal muscle cell transcripts and protein
markers (myoD, myogenin, myosin, and Myf5). In vitro calcium labeling studies showed that
skeletal myogenic differentiated USCs resulted in increased calcium efflux. After the induced
cells (1x106) mixed with 2% collagen-I gel (100 µl) were implanted into the tibialis anterior
muscle of nude mice for one month, the grafted cells maintained expression of skeletal muscle
cell markers in vivo. The USCs differentiated into a skeletal muscle cell lineage, which could
be used as a potential source for cell injection therapy in the treatment of urethral sphincter
dysfunction.
5. Paracrine factors of USCs
We have recently demonstrated that USCs are able to secrete several angiogenic growth
factors, such as VGEF, PDGF, FGF-1, IGFBP-1 and 3, MMP-9, and angiogenin when UCSs in
culture media were assessed by ELISA. In vivo studies showed that USCs can stimulate the
resident cells to migrate from the host into the graft tissue. More cells with no human nuclear
protein expression were observed in the sites where USCs were implanted, compared to a cell-
free injection sites.
There are several potential advantages to using USCs as a cell source for cell therapy, including
the following: 1) USCs can be easily harvested by a non invasive method and grown in culture;
2) they do not require enzyme digestion or culture on a layer of feeder cells to support cell
growth; 3) they start as one single-cell colony in the initial culture, which creates more
homogeneous cells after differentiation; 4) since they possess telomerase activity, they can
generate more cells and provide a longer life span for tissue regeneration; 5) they possess
higher plasticity and more efficiency when induced to differentiate into other functional cells,
including endothelial and muscle cells; and 6) as autologous cells, USCs do not raise ethical
issues or cause immune reactions to engineered implants. Therefore, obtaining and using stem
cells from urine could be an attractive alternative to the standard urological tissue biopsies
currently used in cell therapy and tissue engineering. Additionally, myogenic differentiated
USCs might be used in other diseases involved in sphincter dysfunction via an endoscopic
procedure, including muscle sphincter-deficient diseases such as vesicoureteral reflux,
gastroesophageal reflux disease [25,26], and anal incontinence [27].
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6. Conclusions
USCs as pericytes/mesenchymal stem cells could be easily obtained by a non invasive ap‐
proach. These cells are able to extensively expand and can be induced to differentiate efficiently
into a skeletal myogenic cell lineage. In addition, myogenically-differentiated USCs expressed
skeletal muscle cell gene and protein markers. Moreover, USCs are able to recruit resident cells
from the host to participate in tissue regeneration by their secretion of paracrine factors. Use
of autologous USCs may serve as a more convenient and low-cost cell source comparable in
quality to other types of adult stem cells, and could generate a large number of cells in vitro
for potential use in treatment of patients with SUI or other diseases due to sphincter deficiency.
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